There is positive news in the development of a coronavirus vaccination: The Mainz-based company Biontech has already started mass production of an active ingredient.
Mainz - The
Mainz company Biontech
has announced a breakthrough.
The
vaccine
called "BNT162b2" works very well.
Even
mass production
has already started.
Theeuropean.de
reports
.
The final approval process has been applied for, but is still missing.
According to the European pharmaceutical regulator EMA in Amsterdam, the vaccine is now being tested in the so-called "rolling review process".
This means that results from
clinical testing are
continuously submitted and analyzed.
Whether the EMA grants approval depends on the positive results of the
clinical studies
so far
.
One is on the verge of "
putting
an end to
this
pandemic
", announced
Biontech
.
Coronavirus vaccination in 2020 would be a historic record
In fact, it would be extremely unusual if
a vaccine could be given
a few months after the
pandemic broke
out.
Because it normally takes several years before a
vaccine is
developed and approved.
But
Federal Health Minister Spahn
is also optimistic.
"As of now, I would assume that we can start in the first quarter of next year," he said at a video conference of the Ifo Institute.
It is also possible that we will have “too much vaccine”.
Because several companies are currently working on the
development of a vaccine
.
In April
,
Biontech
was the first German company to
receive
approval for
clinical studies
.
Meanwhile, 37,000 people have agreed to
take part
in the
study
.
28,000 people have already received the second
dose of vaccine
in more than 120 study centers
, including in the USA, Brazil, South Africa and Argentina.
Coronavirus vaccination is already being produced in large quantities
Four out of
a total of
20 vaccine candidates
have been clinically tested, "BNT162b2" is "very promising," said
Biontech boss
and co-founder
Ugur Sahin
.
He is convinced that "we have a safe product and are able to demonstrate its effectiveness." He will present all data sets and provide transparent information about the
effects
and
side effects
.
Biontech
is so convinced of its
vaccine
that the company bought the production facility of the Swiss pharmaceutical company Novartis with 300 employees in order
to be able to ramp up
mass production
at short notice.
100 million
vaccine doses
are to be created
this year, and
another 250 million in the first half of 2021.
* Merkur.de is part of the nationwide Ippen-Digital editors network.
List of rubric lists: © Christoph Soeder / dpa